VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
NHCNational HealthCare Corporation
$201.53$3.1B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksNHCPrice Target
NHC logo

National HealthCare Corporation (NHC) Price Target Analysis

Analyst Rating:
Based on 0 analysts

No Target Data

NHC trades at Wall Street's consensus target of —.

Current Price$201.53
Average Target—
Low—
Median—
High—

Analyst Target Range

Forward P/E25.3x
(Growth Premium)
PEG Ratio1.10
(Fair)
Implied Growth+1.6%
(Low)
Analyst Spread—

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$201.53
Consensus—
High—
Low—

Consensus Scenario Assumptions

The base valuation assumes NHC achieves its forward estimates and maintains a stable P/E multiple of 25.3x. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings

No analyst coverage available for NHC

Coverage appears once Wall Street estimates are published.

NHC Price Target Analysis

Updated June 21, 2026

As of June 21, 2026, National HealthCare Corporation (NHC) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $3.15B.

Analyst price targets range from a low of N/A to a high of N/A.

The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.

From a valuation perspective, NHC trades at a trailing P/E of 26.3x and forward P/E of 25.3x. The forward PEG ratio of 1.10 indicates reasonable valuation for growth. Analysts expect EPS to grow +1.6% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $234.83, with bear and bull scenarios of $147.94 and $309.41 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+22.3%
Industry Consensus
Avg Forward P/E
32.1x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
EHC logo
EHCEncompass Health Corporation
$9.7B$98.03$146.00
+48.9%
Buy16.3x26
PNTG logo
PNTGThe Pennant Group, Inc.
$1.2B$33.44$39.00
+16.6%
Buy24.7x7
ADUS logo
ADUSAddus HomeCare Corporation
$1.8B$94.23$122.00
+29.5%
Buy13.5x16
CCRN logo
CCRNCross Country Healthcare, Inc.
$426M$13.17$12.50
-5.1%
Hold142.4x14
SEM logo
SEMSelect Medical Holdings Corporation
$2.1B$16.54$17.75
+7.3%
Hold13.6x14
SGRY logo
SGRYSurgery Partners, Inc.
$1.9B$14.55$19.33
+32.9%
Buy33.9x22
CHE logo
CHEChemed Corporation
$6.0B$436.27$475.00
+8.9%
Hold17.9x9
HCSG logo
HCSGHealthcare Services Group, Inc.
$1.6B$22.94$24.50
+6.8%
Hold21.2x15
ENSG logo
ENSGThe Ensign Group, Inc.
$9.0B$153.65$222.33
+44.7%
Buy20.3x13
MCK logo
MCKMcKesson Corporation
$90.2B$750.63$994.86
+32.5%
Buy17.0x31

NHC — Frequently Asked Questions

Quick answers to the most common questions about buying NHC stock.

What is the NHC stock price target for 2026?

The consensus price target for NHC is $N/A, close to the current price of $201.53 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.

Is NHC a buy, sell, or hold?

NHC has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.

Is NHC stock overvalued or undervalued?

NHC trades at a forward P/E of 25.2861x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.

How high can NHC stock go?

The most bullish Wall Street analyst has a price target of $N/A for NHC, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $309 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover NHC stock?

NHC is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the NHC stock forecast?

The 12-month NHC stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A". Our proprietary valuation model produces a base case fair value of $235, with bear/bull scenarios of $148/$309.

What is NHC's fair value based on fundamentals?

Our quantitative valuation model calculates NHC's fair value at $235 (base case), with a bear case of $148 and bull case of $309. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.

What is NHC's forward P/E ratio?

NHC trades at a forward P/E ratio of 25.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 26.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy NHC stock?

NHC appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do NHC price targets vary so much?

NHC analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $148-$309 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare